Telesis Bio (NASDAQ:TBIO) Stock Price Down 6.8%

Telesis Bio, Inc. (NASDAQ:TBIO)’s stock price was down 6.8% during mid-day trading on Friday . The stock traded as low as $0.32 and last traded at $0.33. Approximately 145,341 shares changed hands during mid-day trading, a decline of 75% from the average daily volume of 579,324 shares. The stock had previously closed at $0.35.

Telesis Bio Trading Down 6.8 %

The company has a debt-to-equity ratio of 22.76, a current ratio of 3.71 and a quick ratio of 3.22. The business’s 50 day simple moving average is $0.45 and its 200 day simple moving average is $0.46. The stock has a market cap of $9.93 million, a P/E ratio of -0.20 and a beta of 1.93.

Telesis Bio (NASDAQ:TBIO) last posted its earnings results on Thursday, March 28th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. The business had revenue of $6.98 million during the quarter. Telesis Bio had a negative return on equity of 176.47% and a negative net margin of 173.78%.

About Telesis Bio

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits which contains the necessary building blocks and reagents, including proprietary gibson assembly branded reagents, for specific synthetic biology workflow applications.